<DOC>
	<DOCNO>NCT00447642</DOCNO>
	<brief_summary>This study evaluate use LX201 prevent future graft rejection episodes and/or graft failure patient undergone corneal transplantation recently experience rejection episode due immune response .</brief_summary>
	<brief_title>Study Assess LX201 Prevention Corneal Allograft Rejection Graft Failure Subjects Who Have Experienced One More Rejection Episodes Following Penetrating Keratoplasty</brief_title>
	<detailed_description>LX201 novel sustained-release silicone implant contain 30 % cyclosporine A weight . LX201 intend surgical episcleral placement eye . The study Phase 2/3 , multi-center , placebo-controlled , randomize , parallel-group , dose-ranging study LX201 prevention corneal allograft rejection graft failure subject one rejection episodes follow penetrate keratoplasty . After Visit 12 ( Week 52 ) , subject USA India implant study eye follow safety least per year 2 year period time implant removal . In Germany , implant remove Week 52 3-month safety follow-up period removal .</detailed_description>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Subjects , within 6 month prior study randomization , experience 1 corneal allograft rejection episodes follow penetrate keratoplasty Must stable medical regimen least 14 day time randomization study Conjunctiva must suitable implantation study device Any condition would greatly increase risk nonrejection graft failure StevensJohnson syndrome , xerophthalmia severe exposure keratitis . Schirmer 's test ≤ 5 mm 1 minute . Clinical evidence limbal stem cell deficiency . History active herpes simplex virus keratitis acute corneal infection Subjects &gt; 3 failed graft ipsilateral eye Uncontrolled glaucoma evidence intraocular pressure &gt; 21 mmHg maximal medical therapy Clinically suspect confirm ocular lymphoma Treatment systemic immunosuppressive regimen within previous 30 day ; systemic prednisone ( equivalent ) ≤ 10 mg daily , however , permit . Any implantable corticosteroideluting device ( e.g. , Retisert™ , Posurdex® , Medidur™ , Ivation™ triamcinolone acetonide [ TA ] intravitreal implant ) Subjects periodically require highdose systemic steroid treatment ( e.g. , exacerbation chronic obstructive pulmonary disease ) . Subjects receive treatment monoclonal antibody biologic therapy within previous 90 day alemtuzumab within previous 12 month History herpes zoster varicella infection within 6 week prior enrollment , chicken pox exposure within 21 day enrollment Seropositivity human immunodeficiency virus ( HIV ) Previous exposure know contraindication administration cyclosporine Recipients solid organ transplant Currently participate another clinical trial investigational agent 30 day prior study participation and/or recover reversible effect side effect prior investigational agent Currently pregnant lactate Active , extraocular and/or systemic infection require prolong chronic use antimicrobial agent presence active hepatitis A , B C Current malignancy history malignancy ( within previous 5 year ) except nonmetastatic basal squamous cell carcinoma skin carcinomainsitu cervix treat successfully Active peptic ulcer disease Comorbid condition require immunosuppression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>immunology</keyword>
	<keyword>cornea</keyword>
	<keyword>allograft</keyword>
	<keyword>corneal allograft rejection</keyword>
	<keyword>graft failure</keyword>
</DOC>